Breaking News

AstraZeneca Buys Omthera

Boosts cholesterol portfolio, may form Crestor-combo

By: Gil Roth

President, Pharma & Biopharma Outsourcing Association

AstraZeneca has entered into a definitive agreement to acquire Omthera Pharmaceuticals, a specialty pharmaceutical company based in Princeton, NJ. Omthera is focused on the development and commercialization of new therapies for dyslipidemia. Omthera’s lead product, Epanova, for the potential treatment of patients with very high triglycerides, is a novel omega-3 free fatty acid composition that has been shown to bolster levels of eicosapentaenoic acid and docosahexaenoic acid significantly...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters